Biotie Therapies Corp. Initial Public Offering
Davis Polk advised Biotie Therapies Corp. (“Biotie”) on its $56.7 million U.S. initial public offering of 3,806,047 American Depositary Shares (“ADSs”) representing 304,483,760 ordinary…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Bio-Reference Laboratories $1.47 billion acquisition by OPKO Health
Davis Polk is advising Bio-Reference Laboratories, Inc. in connection with its approximately $1.47 billion acquisition by OPKO Health, Inc. Under the terms of the agreement, holders of Bio…